Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share

by Co-Diagnostics | Nov 2, 2020 | News Release

Salt Lake City, Utah – November 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following the discovery of an incorrectly...

Co-Diagnostics, Inc. Provides Update on “ABC” Test for Influenza A, Influenza B, and COVID-19

by Co-Diagnostics | Sep 24, 2020 | News Release

Company expects to begin taking orders from US CLIA labs first week of October 2020 Salt Lake City, Utah – September 24, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of...

Co-Diagnostics, Inc. Announces Details to Access Presentation at H.C. Wainwright Global Investment Conference

by Co-Diagnostics | Sep 11, 2020 | News Release

Salt Lake City, Utah – September 11, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced the access details for CEO Dwight Egan’s...

Co-Diagnostics, Inc. Enters into Agreement with Arches Research to Expand COVID-19 Testing Services

by Co-Diagnostics | Sep 8, 2020 | News Release

Salt Lake City, Utah – September 8, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced that it has entered into an agreement with Arches...

Co-Diagnostics, Inc. Issues Operational Update

by Co-Diagnostics | Sep 1, 2020 | Market Update, News Release

Salt Lake City, Utah – September 1, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, issued the following statement concerning the progress of the...

Co-Diagnostics, Inc. To Discuss Recent Company Growth and Upcoming Expansion Plans at H.C. Wainwright Global Investment Conference

by Co-Diagnostics | Aug 25, 2020 | News Release

Salt Lake City, Utah – August 25, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Company CEO Dwight Egan will be discussing the...